Francisco Ortiz, MD
Family Medicine · Houston, TXNPI 1174545461
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Astellas Pharma US Inc at 24.9% of the total. That places this record below the midpoint for family medicine clinicians in TX, where the typical reported total is $436.
Across 29 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$110
- Amgen$77
- AstraZeneca$62
- Mannkind Corporation$56
- Johnson & Johnson$29
- Novo Nordisk$29
- plus $78 from 5 others
Across 152 payments — averaging $11,073 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.1M
- Insmed, Inc.$163K
- Currax Pharmaceuticals LLC$132K
- Sanofi$126K
- AstraZeneca$90K
- Teva Pharmaceuticals USA, Inc.$29K
- plus $61K from 3 others
What the payments were for
- Food & beverage$440100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 8 | $110 |
| Amgen(2 entities) | 5 | $77 |
| AstraZeneca | 4 | $62 |
| Mannkind Corporation | 3 | $56 |
| Johnson & Johnson | 2 | $29 |
| Novo Nordisk | 2 | $29 |
| Genentech USA, Inc. | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| AbbVie | 1 | $11 |
| Merck | 1 | $11 |
How this compares
$440 in reported general payments places this provider in the 50th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 18 | $16,359 |
| Cefdinir | 41 | $821 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $668 |
| Atorvastatin Calcium | 89 | $379 |
| Gabapentin | 37 | $355 |
| Diclofenac Sodium | 14 | $341 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 25 | $309 |
| Lisinopril | 46 | $284 |
| Azithromycin | 49 | $250 |
| Ketorolac Tromethamine | 14 | $227 |
| Metformin Hcl | 85 | $212 |
| Levothyroxine Sodium | 37 | $207 |
| Dicyclomine Hcl | 12 | $196 |
| Meclizine Hcl | 22 | $196 |
| Ondansetron OdtOndansetron | 22 | $187 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Houston
- Shannon SchraderHouston$216K
- Candice WinfulHouston$173K
- Guljeet SohalHouston$72K
- Lakecia PittsHouston$71K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.